At present, treating of triple negative breast cancer (TNBC) mainly depends on
chemotherapy with more toxic side effects, but the effect is limited and it is highly prone to …

Metastatic relapse, development of drug resistance in cancer cells and adverse side effects
of chemotherapeutic agents are the major obstacles for effective chemotherapy against triple …

Triple-negative breast cancer is an aggressive form of breast cancer with few therapeutic
options if it recurs after adjuvant chemotherapy. RNA interference could be an alternative …

Co-delivery of microRNAs and chemotherapeutic drugs into tumor cells is an attractive
strategy for synergetic breast cancer therapy due to their complementary mechanisms. In …

In this study, a chitosan-based, self-assembled nanosystem that codelivered microRNA34a
(miR34a) and doxorubicin (Dox) with hyaluronic acid (HA) modification (named CCmDH …

Background Triple negative breast cancer (TNBC) is one of the most biologically aggressive
breast cancers and lacks effective treatment options, resulting in a poor prognosis …

The development of new therapeutic strategies to target triple-negative breast cancer
(TNBC) is in much demand to overcome the roadblocks associated with the existing …

The challenge in HER2-overexpressing breast cancer therapy lies in creating an effective
target therapy to overcome treatment resistance. Monoclonal antibodies and target gene …

Small-molecule chemosensitizers can reverse cancer multidrug resistance (MDR), thus
significantly improving the in vitro effect of chemotherapy drugs for MDR cancer cells …

Triple negative breast cancer (TNBC) is the most aggressive and lethal subtype of breast
cancer. It is associated with a very poor prognosis and intrinsically resistant to several …